Nanoparticle Gel System Delivers Liraglutide Directly to Gums for Diabetic Gum Disease

PLGA/HA nanoparticles loaded with liraglutide provided sustained local release that reduced diabetic periodontitis severity by inhibiting necroptosis in periodontal tissues, addressing both glycemic control and local tissue destruction.

Animal study in diabetic rats with periodontitis. Developed and characterized PLGA nanoparticles loaded with liraglutide in a HA scaffold. Assessed particle morphology, size, drug release kinetics, and in vivo efficacy on periodontal inflammation and bone loss.

Diabetic periodontitis is a common complication where systemic diabetes worsens local gum disease, and vice versa. Local delivery of a GLP-1 drug addresses both problems simultaneously — controlling blood sugar locally while reducing the inflammatory destruction of gum tissue.

This illustrates the growing potential of peptide drugs beyond their primary indications. Liraglutide was designed for systemic diabetes management, but local delivery to specific tissues could unlock entirely new therapeutic applications, from dental to wound healing.

Animal study in rats — dental anatomy and disease progression differ from humans; long-term stability and degradation of the HA/PLGA system in the oral environment needs assessment; comparison with standard periodontal treatments not performed; scale-up for clinical use unaddressed.